Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 79 Days Sales Outstanding is 21.43 as of Jun. 2026, which is 130% above its 10-year median of 9.30. GuruFocus rates MNIVF with a GF Score™ of 79/100 and a GF Value™ of $0.61. The stock has 10 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 96.02% on this metric.
The historical rank and industry rank for Monash IVF Group's Days Sales Outstanding or its related term are showing as below:
MNIVF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.27 Med: 9.3 Max: 18.4
Current: 18.4
During the past 13 years, Monash IVF Group's highest Days Sales Outstanding was 18.40. The lowest was 8.27. And the median was 9.30.
MNIVF's Days Sales Outstanding is ranked better than 96.02% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs MNIVF: 18.40
Monash IVF Group's Days Sales Outstanding
declined
from Jun. 2025 (31.26) to Jun. 2026 (21.43).
Monash IVF Group (OTCPK:MNIVF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Monash IVF Group Days Sales Outstanding Related Terms
Monash IVF Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNIVF vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's Days Sales Outstanding falls into.
Monash IVF Group Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a Days Sales Outstanding of 21.43 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Monash IVF Group and its competitors. This is 130% above median its historical median of 9.30. Over the past decade, Monash IVF Group's Days Sales Outstanding has ranged from 8.27 to 18.40. According to the industry distribution chart, Monash IVF Group ranks #8 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 4%.
Is Monash IVF Group's Days Sales Outstanding too high?
Monash IVF Group's current Days Sales Outstanding of 21.43 is 130% above median its 10-year median of 9.30. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 18.40. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Monash IVF Group's value of 21.43 is 68.3% below this industry median. Based on the distribution chart, Monash IVF Group ranks #8 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Monash IVF Group has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #8 out of 201 companies for Days Sales Outstanding. This places Monash IVF Group in the top 4% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.59. Monash IVF Group's value of 21.43 is 68.3% below this benchmark. Historically, Monash IVF Group's own Days Sales Outstanding has ranged from 8.27 to 18.40 over the past decade. While the company's 10-year median is 9.30 vs. the industry median of 67.59, Monash IVF Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current Days Sales Outstanding of 21.43 is 68.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current Days Sales Outstanding is 21.43, which is 130% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current Days Sales Outstanding of 21.43. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current Days Sales Outstanding is 21.43, which is 130% above median its 10-year median of 9.30 and 68.3% below the Medical Diagnostics & Research industry median of 67.59. Monash IVF Group's overall GF Score™ is 79/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current Days Sales Outstanding is 21.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
Key valuation signals for MNIVF:
Days Sales Outstanding: 21.43 (130% above median its 10-year median of 9.30)
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
Industry Position: 68.3% below the Medical Diagnostics & Research median (#8 of 201)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
79GF Score
Get the complete analysis for MNIVF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
